7008-63-1

Usage

Uses

Used in Pharmaceutical Research:
Imidazo[2,1-b]thiazole,6-phenylis used as a reagent in organic synthesis and medicinal chemistry research for the development of new pharmaceuticals. Its unique structure and potential biological activities make it a valuable compound for exploring novel therapeutic agents.
Used in Drug Development:
Imidazo[2,1-b]thiazole,6-phenylhas shown promise as a potential drug candidate for the treatment of various diseases. Its effects on different biological targets and pathways make it a valuable starting point for the development of new therapeutic agents.
Used in Organic Synthesis:
Imidazo[2,1-b]thiazole,6-phenylis utilized as a reagent in organic synthesis, where its unique structure can be modified to create new compounds with potential applications in various fields, including pharmaceuticals, agrochemicals, and materials science.

InChI:InChI=1/C11H8N2S/c1-2-4-9(5-3-1)10-8-13-6-7-14-11(13)12-10/h1-8H

Upstream product

• 96-50-4 2-thiazolylamine 
• 70-11-1 α-bromoacetophenone 
• 127801-93-8 ethyl 6-phenylimidazo<2,1-b>thiazole-5-carboxylate 
• 6692-24-6 2-imino-3-phenacyl-2,3-dihydrothiazole 
• 7664-93-9 sulfuric acid 
• 101496-48-4 2-(4-phenyl-1⁽³⁾H-imidazol-2-ylmercapto)-acetaldehyde-diethylacetal 
• 98-86-2 acetophenone 
• 389614-52-2 α-[(2,4-dinitrobenzene)sulfonyl]oxyacetophenone 
• 613-91-2 acetophenone oxime 
• 752244-05-6 ethyl 6-phenylimidazo [2,1-b]thiazole-3-carboxylate 
• 349481-08-9 ethyl 6-phenylimidazo[2,1-b][1,3]thiazole-2-carboxylate 
• 100-41-4 ethylbenzene 
• 6039-97-0 3H-thiazol-2-one 
• 6857-34-7 4-phenyl-1,3-dihydro-2H-imidazole-2-thione 

Downstream Products

• 99974-06-8 4-imidazo[2,1-b]thiazol-6-yl-benzenesulfonic acid 
• 16311-32-3 (6-phenyl-imidazo[2,1-b]thiazol-5-yl)-succinic acid 
• 14954-71-3 6-phenyl-5-phenylazo-imidazo[2,1-b]thiazole 
• 14954-66-6 5-(4-nitro-phenylazo)-6-phenyl-imidazo[2,1-b]thiazole 
• 14956-60-6 5-(2-nitro-phenylazo)-6-phenyl-imidazo[2,1-b]thiazole 
• 74630-73-2 6-phenylimidazo[2,1-b]thiazole-5-carbaldehyde 
• 14956-61-7 5-(3-nitro-phenylazo)-6-phenyl-imidazo[2,1-b]thiazole 
• 16311-29-8 N,N''-(6-phenyl-imidazo[2,1-b]thiazole-2,5-diyl)-bis-hydrazine-N,N'-dicarboxylic acid tetraethyl ester 
• 93327-30-1 4-(6-phenyl-imidazo[2,1-b]thiazol-5-ylazo)-benzenesulfonic acid 
• 99866-35-0 5-bromo-6-phenylimidazo[2,1-b]thiazole 
• 99866-92-9 2-nitroso-6-phenyl-imidazo[2,1-b]thiazole 
• 16311-38-9 5-nitro-6-(4-nitro-phenyl)-imidazo[2,1-b]thiazole 
• 7120-14-1 6-p-nitrophenylimidazo<2,1-b>thiazole 
• 16311-34-5 5-nitroso-6-phenylimidazo[2,1-b][1,3]thiazole 

Relevant academic research and scientific papers

Synthesis, crystal structure, antimicrobial activity and docking studies of new imidazothiazole derivatives

A series of imidazothiazole derivatives were synthesized via Claisen–Schmidt condensation of aldehyde 3, and different methyl ketones and their chemical structures were confirmed using 13C NMR, 1H NMR and LC–MS. In addition, the mole

Discovery of New Imidazo[2,1- b]thiazole Derivatives as Potent Pan-RAF Inhibitors with Promising in Vitro and in Vivo Anti-melanoma Activity

BRAF is an important component of MAPK cascade. Mutation of BRAF, in particular V600E, leads to hyperactivation of the MAPK pathway and uncontrolled cellular growth. Resistance to selective inhibitors of mutated BRAF is a major obstacle against treatment of many cancer types. In this work, a series of new (imidazo[2,1-b]thiazol-5-yl)pyrimidine derivatives possessing a terminal sulfonamide moiety were synthesized. Pan-RAF inhibitory effect of the new series was investigated, and structure-activity relationship is discussed. Antiproliferative activity of the target compounds was tested against the NCI-60 cell line panel. The most active compounds were further tested to obtain their IC50 values against cancer cells. Compound 27c with terminal open chain sulfonamide and 38a with a cyclic sulfamide moiety showed the highest activity in enzymatic and cellular assay, and both compounds were able to inhibit phosphorylation of MEK and ERK. Compound 38a was selected for testing its in vivo activity against melanoma. Cellular and animal activities are reported.

Electrochemical Oxidative C3 Acyloxylation of Imidazo[1,2- a]pyridines with Hydrogen Evolution

The C3-functionalized imidazo[1,2-a]pyridines are versatile nitrogen-fused heterocycles; however, the methods for the C3 acyloxylation of imidazo[1,2-a]pyridines have never been reported. Herein we demonstrate the electrochemical oxidative C3 acyloxylation of imidazo[1,2-a]pyridines for the first time. Notably, by using electricity, the electrochemical oxidative C3 acyloxylation of imidazo[1,2-a]pyridines was carried out under mild conditions. Moreover, in addition to aromatic carboxylic acids, alkyl carboxylic acids were also competent substrates.

Micellar Catalysis: Visible-Light Mediated Imidazo[1,2-a]pyridine C—H Amination with N-Aminopyridinium Salt Accelerated by Surfactant in Water

A light-promoted metal-free protocol for the amination of imidazo[1,2-a]pyridines with N-aminopyridinium salt by the assistance of surfactants in water was reported, charactering mild and environmentally benign conditions, as well as great functional grou

New imidazo[2,1-: B] thiazole-based aryl hydrazones: Unravelling their synthesis and antiproliferative and apoptosis-inducing potential

Herein, we have designed and synthesized new imidazo[2,1-b]thiazole-based aryl hydrazones (9a-w) and evaluated their anti-proliferative potential against a panel of human cancer cell lines. Among the synthesized compounds, 9i and 9m elicited promising cytotoxicity against the breast cancer cell line MDA-MB-231 with IC50 values of 1.65 and 1.12 μM, respectively. Cell cycle analysis revealed that 9i and 9m significantly arrest MDA-MB-231 cells in the G0/G1 phase. In addition, detailed biological studies such as annexin V-FITC/propidium iodide, DCFH-DA, JC-1 and DAPI staining assays revealed that 9i and 9m triggered apoptosis in MDA-MB-213 cells. Overall, the current work demonstrated the cytotoxicity and apoptosis-inducing potential of 9i and 9m in breast cancer cells and suggested that they could be explored as promising antiproliferative leads in the future. This journal is

CuCl2-catalyzed N[sbnd]O bond cleavage of oxime esters: Approach to imidazoheterocycles and furo[3,2-c]chromenyl fused imidazoles

An articulate approach to a diverse set of imidazoheterocycles in good to high yields via a copper-catalyzed aza-annulation of several oxime esters with a group of 2-amino-azaarenes was developed. The above cyclization reaction probably proceeds via a single electron transfer process which embodies a new technique for creating two new C[sbnd]N bonds for imidazole ring synthesis. Gratifyingly, the implementation of this chemistry could be further stretched to the synthesis of a novel class of fused imidazoles bearing a furo[3,2-c]chromene moiety via a sequential C[sbnd]N bond formation, followed by C(sp2)-H functionalization/5-endo-dig-oxacyclization (C[sbnd]C and C[sbnd]O bonds) of in situ produced fused imidazoles with cyclic enynones in the presence of copper(II) as a π-electrophilic Lewis acid catalyst.

SELECTIVE LIGANDS OF HUMAN CONSTITUTIVE ANDROSTANE RECEPTOR

The present invention provides a structurally novel class of heterocyclic compounds of general formula I wherein L1 is heteroaryl and L2 is heteroaryl or aryl. The novel compounds are useful in a method of prevention or treatment of a condition which is m

Transition-Metal-Free Direct Trifluoromethylation and Perfluoroalkylation of Imidazopyridines under Mild Conditions

The first transition-metal-free method for direct C?H trifluoromethylation of imidazo[1,2-a]pyridine derivatives with readily available Ruppert-Prakash reagent TMSCF3 under mild conditions was described. Moreover, this method could be applied to direct C?H perfluoroalkylation of imidazopyridines, affording a series of novel perfluoroalkylated products in moderate to good yields. Notable advantages of this protocol include easy operation, high-efficiency and wide substrate scope. (Figure presented.).

DL5050, a Selective Agonist for the Human Constitutive Androstane Receptor

The constitutive androstane receptor (CAR) is a xenobiotic sensor governing the transcription of genes involved in drug disposition, energy homeostasis, and cell proliferation. However, currently available human CAR (hCAR) agonists are nonselective, which

Human constitutive androstane receptor agonist DL5016: A novel sensitizer for cyclophosphamide-based chemotherapies

The DNA alkylating prodrug cyclophosphamide (CPA), alone or in combination with other agents, is one of the most commonly used anti-cancer agents. As a prodrug, CPA is activated by cytochrome P450 2B6 (CYP2B6), which is transcriptionally regulated by the